Biotechnology
Biopharmaceutical
Pharmaceutical

Ziopharm Oncology

$4.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.07 (1.72%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ZIOP and other stocks, options, ETFs, and crypto commission-free!

About

ZIOPHARM Oncology Inc Common Stock, also called Ziopharm Oncology, is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. Read More The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Employees
48
Headquarters
Boston, Massachusetts
Founded
2003
Market Cap
653.93M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.53M
High Today
$4.22
Low Today
$3.96
Open Price
$4.05
Volume
1.20M
52 Week High
$5.00
52 Week Low
$1.56

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Cancer Prevention
Health
Therapy
Technology
US

News

Seeking AlphaMar 5

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q4 2018 Results - Earnings Call Transcript

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Q4 2018 Earnings Conference Call March 5, 2019 4:30 PM ET Company Participants David Connolly - IR Laurence Cooper - CEO David Mauney - President Conference Call Participants Reni Benjamin - Raymond James Eric Joseph - J.P. Morgan Sean Lee - H. C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Ziopharm Fourth Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answe...

313
Yahoo FinanceMar 5

Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

- Phase 1 Trial of Sleeping Beauty-TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 – - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 – - Eden BioCell to advance third-generation Sleeping Beauty CAR-T for Greater China – - Third cohort enrolling patients in Controlled IL-12 combination trial with OPDIVO® for recurrent glioblastoma (rGBM) – - Phase 2 trial of Controlled IL-12 in combination with Regeneron’s Libtayo® f...

178
MarketBeatMar 3

Stock Price, News, & Analysis for ZIOPHARM Oncology

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic...

13

Earnings

-$0.15
-$0.13
-$0.10
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.